|
Obesity
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TWEAK was expressed in adipose tissue of all studied subjects with no differences between obesity group, and was associated with Fn14 expression in morbid obese, mainly in women with type 2 diabetes.
|
16503147 |
2006 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TWEAK was expressed in adipose tissue of all studied subjects with no differences between obesity group, and was associated with Fn14 expression in morbid obese, mainly in women with type 2 diabetes.
|
16503147 |
2006 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
TWEAK serum concentrations were elevated in stroke patients.
|
18793781 |
2008 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
TWEAK also increases migration and invasion in wt and p38α deficient MEFs, which indicates that p38α MAPK is not required to mediate these effects.
|
28383766 |
2018 |
|
Atherosclerotic lesion
|
0.010 |
Biomarker
|
disease |
BEFREE |
TWEAK blockade decreases atherosclerotic lesion size and progression through suppression of STAT1 signaling in diabetic mice.
|
28447667 |
2017 |
|
Dermatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
TWEAK is therefore a critical contributor to skin inflammation and a possible therapeutic target in AD and psoriasis.
|
28530223 |
2017 |
|
Inflammatory dermatosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
TWEAK is therefore a critical contributor to skin inflammation and a possible therapeutic target in AD and psoriasis.
|
28530223 |
2017 |
|
Dermatitis, Atopic
|
0.010 |
Biomarker
|
disease |
BEFREE |
TWEAK is therefore a critical contributor to skin inflammation and a possible therapeutic target in AD and psoriasis.
|
28530223 |
2017 |
|
Eczema
|
0.010 |
Biomarker
|
disease |
BEFREE |
TWEAK is therefore a critical contributor to skin inflammation and a possible therapeutic target in AD and psoriasis.
|
28530223 |
2017 |
|
Psoriasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
TWEAK is therefore a critical contributor to skin inflammation and a possible therapeutic target in AD and psoriasis.
|
28530223 |
2017 |
|
Manic episode
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TWEAK levels of ME and RE groups were significantly lower than HC.
|
28800513 |
2017 |
|
Cardiovascular Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
TNF-related weak inducer of apoptosis (TWEAK), an inflammatory mediator implicated in the development of cardiovascular diseases, could be a mechanism for such effect.
|
29548604 |
2018 |
|
Heart failure
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TWEAK (TNF-Related WEAK Inducer Of Apoptosis), a NF-κB- and/or AP-1-responsive proinflammatory cytokine that signals via TWEAK receptor (TWEAKR), is expressed at high levels in human and preclinical models of HF.
|
29981796 |
2018 |
|
Congestive heart failure
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TWEAK (TNF-Related WEAK Inducer Of Apoptosis), a NF-κB- and/or AP-1-responsive proinflammatory cytokine that signals via TWEAK receptor (TWEAKR), is expressed at high levels in human and preclinical models of HF.
|
29981796 |
2018 |
|
Polycystic Ovary Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
TWEAK and monocyte to HDL ratio as a predictor of metabolic syndrome in patients with polycystic ovary syndrome.
|
30241442 |
2019 |
|
Cardiovascular Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
TWEAK and monocyte/HDL ratio may be promising in predicting MS at early stages in PCOS to prevent future cardiovascular diseases by modifying life-style or giving pharmacotheraphy.
|
30241442 |
2019 |
|
Subarachnoid Hemorrhage
|
0.010 |
Biomarker
|
disease |
BEFREE |
TNFSF12 also increased the risk of subarachnoid (OR=1.53; 95% CI, 1.31-1.78; P=3.32×10<sup>-8</sup>) and intracerebral (OR=1.34; 95% CI, 1.14-1.58; P=4.05×10<sup>-4</sup>) hemorrhages, whereas SCARA5 decreased the risk of subarachnoid hemorrhage (OR=0.61; 95% CI, 0.47-0.81; P=5.20×10<sup>-4</sup>).
|
31208196 |
2019 |
|
Diastolic blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure.
|
29455858 |
2018 |
|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure.
|
29455858 |
2018 |
|
Bipolar Disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Aim of this study is to detect serum TWEAK and TRAIL levels of patients with bipolar disorder and healthy controls.
|
28800513 |
2017 |
|
Neural Tube Defects
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Among 84 key genes involved in programmed cell death, 13 genes, including tumor necrosis factor (Tnf), annexin A5, apoptosis inhibitor 5, Bcl2‑associated athanogene 3, baculoviral IAP repeat‑containing 3, caspase (Casp)12, Casp4, Casp8, lymphotoxin β receptor, NLR family, apoptosis inhibitory protein 2, TNF receptor superfamily (Tnfrsf)1a, TNF superfamily (Tnfs)f10 and Tnfsf12, were downregulated, whereas nucleolar protein 3 was upregulated in the RA‑induced NTD mice.
|
29693124 |
2018 |
|
Common Variable Immunodeficiency
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
Antibody deficiency associated with an inherited autosomal dominant mutation in TWEAK.
|
23493554 |
2013 |
|
Malignant neoplasm of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis.
|
24970477 |
2014 |
|
Prostate carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis.
|
24970477 |
2014 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
As malignant cell apoptosis is strongly enhanced by secondary oligomerization of TRAIL, we tested the hypothesis that soluble Fn14·TRAIL can be oligomerized and become more active by adding TWEAK, a cytokine secreted in the tumor environment.
|
28455246 |
2017 |